Solving Cell Therapy’s Dirty Secret: How One Partnership Could Unlock Consistent Treatments

Mesenchymal stromal cells (MSCs) have tantalized the medical world for years. These versatile immune-modulating cells offer genuine hope for diseases ranging from epidermolysis bullosa, a genetic disorder where skin tears…

Continue Reading Solving Cell Therapy’s Dirty Secret: How One Partnership Could Unlock Consistent Treatments

After Losing His Mother to Pancreatic Neuroendocrine Tumors, Michael Fitzpatrick Is Now a 26-Year Survivor of the Same Condition

Editor's Note: Patient Worthy is honored to present this article, shared with us by our friends at the Seena Magowitz Foundation. When doctors diagnosed Michael Fitzpatrick with pancreatic neuroendocrine tumors…

Continue Reading After Losing His Mother to Pancreatic Neuroendocrine Tumors, Michael Fitzpatrick Is Now a 26-Year Survivor of the Same Condition

Labcorp Brings Breakthrough Diagnostic to Identify Platinum-Resistant Ovarian Cancer Patients

Labcorp announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only FDA-approved companion diagnostic designed to identify patients with platinum-resistant ovarian cancer who may be eligible for…

Continue Reading Labcorp Brings Breakthrough Diagnostic to Identify Platinum-Resistant Ovarian Cancer Patients

Daraxonrasib Delivers Landmark Survival Gains in Previously Treated Metastatic Pancreatic Cancer

As reported on drugs.com, Revolution Medicines has reported practice-changing efficacy results from a pivotal Phase 3 trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), one of the…

Continue Reading Daraxonrasib Delivers Landmark Survival Gains in Previously Treated Metastatic Pancreatic Cancer

FDA Priority Review Accelerates Path for IMAAVY as First Treatment for Warm Autoimmune Hemolytic Anemia

Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to IMAAVY® (nipocalimab-aahu), marking a significant milestone as the first therapy to receive this…

Continue Reading FDA Priority Review Accelerates Path for IMAAVY as First Treatment for Warm Autoimmune Hemolytic Anemia